Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms.
Bone marrow microenvironment
Bone marrow stromal cell
Clonal hematopoiesis
Myeloid neoplasm
Senescence
Senolytics
Journal
Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
31
03
2024
revised:
24
05
2024
accepted:
02
07
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
epublish
Résumé
Therapy-related myeloid neoplasms (t-MN) are a growing concern due to the continued use of cytotoxic therapies to treat malignancies. Cytotoxic therapies have been shown to drive therapy-induced senescence in normal tissues, including in the bone marrow microenvironment (BMME), which plays a crucial role in supporting normal hematopoiesis. This review examines recent work that focuses on the contribution of BMME senescence to t-MN pathogenesis, as well as offers a perspective on potential opportunities for therapeutic intervention.
Identifiants
pubmed: 39072049
doi: 10.1016/j.jbo.2024.100620
pii: S2212-1374(24)00100-3
pmc: PMC11280103
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100620Informations de copyright
© 2024 Published by Elsevier GmbH.
Déclaration de conflit d'intérêts
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Angelo Jose Guilatco reports financial support was provided by National Cancer Institute. Angelo Jose Guilatco reports financial support was provided by the University of Michigan. Megan Moore Weivoda reports financial support was provided by National Institute on Aging. Megan Moore Weivoda reports a relationship with National Institute of Arthritis and Musculoskeletal and Skin Diseases that includes: funding grants. Mithun Vinod Shah reports a relationship with AbbVie Inc that includes: funding grants. Mithun Vinod Shah reports a relationship with Bristol Myers Squibb Co that includes: funding grants. Mithun Vinod Shah reports a relationship with Astellas Pharma US Inc that includes: funding grants. Mithun Vinod Shah reports a relationship with MRKR Therapeutics that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.